Moody's: Cardinal Health's planned acquisition of Generic Drug is credit positive

New York, June 05, 2015 -- Moody's Investors Service said that it views Cardinal Health, Inc.'s announced $1.115 billion acquisition of Harvard Drug Group (HDG), the operating subsidiary of Generic Drug Holdings, Inc., as credit positive. HDG is a privately-owned telemarketing distributor of generic drugs and over-the-counter (OTC) products. As such, the acquisition will complement Cardinal's own generic drug telemarketing business. At this time, however, there is no change to Cardinal's Baa2 rating or stable outlook. For further information, please see Moody's Issuer Comment on Cardinal Health on www.moodys.com.

Vollständigen Artikel bei Moodys lesen